GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Elanco Animal Health ELAN · USD

Health Care · US listing · 🇺🇸 United States

Compare

26.84

+4.27%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$4.71bn

FY2016FY2025

Net income

−$232.0m

FY2016FY2025

Free cash flow

$284.0m

FY2016FY2025

Shareholders' equity

$6.55bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$4.71bn$4.44bn$4.42bn$4.41bn$4.76bn$3.27bn$3.07bn$3.07bn$2.89bn$2.91bn
Gross profit$2.05bn$1.91bn$1.94bn$1.97bn$2.08bn$1.25bn$1.40bn$1.30bn$1.17bn$1.33bn
Research and development$368.0m$344.0m$327.0m$321.0m$369.0m$327.0m$270.1m$246.6m$251.7m$265.8m
Operating income$252.0m$486.0m$326.0m$384.0m$304.0m−$76.8m$157.1m$313.8m$142.4m$283.2m
Net income−$232.0m$338.0m−$1.23bn−$78.0m−$483.0m−$560.1m$67.9m$86.5m−$310.7m−$47.9m
Diluted earnings per share-0.470.68-2.50-0.16-0.99-1.150.180.24-0.85-0.16

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$13.36bn$12.61bn$14.36bn$15.49bn$16.48bn$17.69bn$8.99bn$8.96bn$8.94bn$8.10bn
Cash and short-term investments$545.0m$468.0m$352.0m$345.0m$638.0m$495.0m$334.0m$474.8m$323.4m$258.8m
Total liabilities$6.81bn$6.52bn$8.14bn$8.20bn$8.97bn$9.22bn$3.44bn$3.76bn$1.15bn$1.07bn
Debt$4.02bn$4.32bn$5.77bn$5.84bn$6.32bn$6.13bn$2.35bn$2.47bn——
Shareholders' equity$6.55bn$6.10bn$6.22bn$7.29bn$7.51bn$8.48bn$5.55bn$5.20bn$7.79bn$7.03bn
Shares outstanding497m494m493m489m487m486m375m366m366m293m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$560.0m$541.0m$271.0m$452.0m$483.0m−$41.0m$224.1m$487.3m$173.8m$155.9m
Capital spending−$276.0m−$147.0m−$154.0m−$184.0m−$197.0m−$310.9m−$197.4m−$134.5m−$98.6m−$110.3m
Free cash flow$284.0m$394.0m$117.0m$268.0m$286.0m−$351.9m$26.7m$352.8m$75.2m$45.6m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$1.37bn$1.37bn$1.14bn$1.14bn$1.24bn$1.19bn$1.02bn$1.03bn
Gross profit$798.0m$785.0m$450.0m$607.0m$577.0m$556.0m$389.0m$405.0m
Operating income$168.0m$144.0m$19.0m$27.0m$85.0m$100.0m$8.0m$617.0m
Net income$54.0m$57.0m−$276.0m−$34.0m$11.0m$67.0m−$8.0m$364.0m
Diluted earnings per share0.110.11-0.56-0.070.020.13-0.020.74
Cash from operations$277.0m$13.0m$108.0m$219.0m$237.0m−$4.0m$177.0m$162.0m
Capital spending−$33.0m−$51.0m−$62.0m−$92.0m−$57.0m−$65.0m−$53.0m−$42.0m
Free cash flow$244.0m−$38.0m$46.0m$127.0m$180.0m−$69.0m$124.0m$120.0m
Total assets$13.56bn$13.22bn$13.36bn$13.55bn$13.74bn$12.94bn$12.61bn$13.28bn
Cash and short-term investments$530.0m$428.0m$545.0m$505.0m$539.0m$487.0m$468.0m$490.0m
Debt$3.92bn$3.99bn$4.02bn$4.02bn$4.21bn$4.39bn$4.32bn$4.36bn
Shareholders' equity$6.59bn$6.50bn$6.55bn$6.75bn$6.78bn$6.35bn$6.10bn$6.52bn

Financial ratios

Data as of 3 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin43.5%43.0%43.9%44.7%43.6%38.1%
Operating margin5.3%10.9%7.4%8.7%6.4%-2.3%
Net margin-4.9%7.6%-27.9%-1.8%-10.1%-17.1%
Return on equity-3.5%5.5%-19.8%-1.1%-6.4%-6.6%
Return on assets-1.7%2.7%-8.6%-0.5%-2.9%-3.2%
Free cash flow yield7.6%6.3%3.9%5.9%6.3%2.5%
Revenue growth6.2%0.5%0.1%-7.4%45.5%6.6%
Earnings growth-168.6%-127.5%1478.2%-83.9%-13.8%-924.9%
Current ratio2.17x2.44x2.75x1.93x1.99x1.65x
Debt to equity0.61x0.71x0.93x0.80x0.84x0.72x
Equity ratio49.0%48.3%43.3%47.1%45.6%47.9%
Interest coverage1.15x1.43x1.18x1.50x1.15x-0.49x
R&D as a share of sales7.8%7.7%7.4%7.3%7.7%10.0%
Buybacks as a share of market value-0.5%-0.3%-0.9%-0.2%-0.2%-29.7%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue2.2%7.6%4.9%
Operating income-13.1%—46.9%
Net income43.8%-16.2%1.0%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin43.2%43.7%43.0%43.1%
Operating margin8.1%8.1%6.4%6.3%
Net margin1.2%-6.7%-8.6%-6.5%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Price to earnings-48.517.7-6.0-76.5-28.6-26.6162.6133.3
Price to sales2.41.41.71.42.94.63.63.8

Market value over time

28 Sept 2018 to 2 Oct 2026, in USD

$10.22bn$11.20bn

Share price return

Finished calendar years

20252024202320222021202020192018
Return88%-18%21%-58%-5%3%-8%-13%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.